Stoke Therapeutics ( (STOK) ) has released its Q3 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Stoke Therapeutics, Inc., a biotechnology company specializing in RNA medicine to restore protein expression, is advancing its lead investigational medicine, zorevunersen, for Dravet syndrome.
In its third-quarter 2025 financial report, Stoke Therapeutics highlighted ongoing patient recruitment for its global Phase 3 EMPEROR study and a robust financial position with $328.6 million in cash and equivalents, expected to fund operations through mid-2028.
The company reported a significant increase in revenue to $10.6 million for Q3 2025, driven by agreements with Acadia and Biogen. However, it also recorded a net loss of $38.3 million, attributed to increased research and development expenses. The company is actively expanding its pipeline with the Phase 1 OSPREY study for STK-002 in ADOA and ongoing lead optimization for SYNGAP1 treatment.
Looking ahead, Stoke Therapeutics plans to meet with the FDA to discuss expedited regulatory pathways for zorevunersen, reflecting the company’s commitment to advancing its clinical programs and potential commercialization efforts.